Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of TBAJ-587 in healthy adults
NL-OMON54986Phase 1Active, not recruiting
- Sponsor
- TB Alliance
- Start
- Dec 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Tuberculosis (TB) comparing TBAJ-587 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single and multiple doses of TBAJ-587, Single ascending dose pharmacokinetics of TBAJ-587 and metabolites and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
TBAJ-587
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON54986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54986.